第一作者单位:[1]Changzheng Hosp, Dept Pharm, Shanghai, Peoples R China
推荐引用方式(GB/T 7714):
Hou X.,Wan X.,Li Y.,et al.COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS DAPAGLIFLOZIN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN CHINA[J].VALUE IN HEALTH.2019,22:S144-S144.doi:10.1016/j.jval.2019.04.574.
APA:
Hou, X.,Wan, X.,Li, Y.,Ding, Y.&Wu, B..(2019).COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS DAPAGLIFLOZIN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN CHINA.VALUE IN HEALTH,22,
MLA:
Hou, X.,et al."COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS DAPAGLIFLOZIN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN CHINA".VALUE IN HEALTH 22.(2019):S144-S144